Although not justifiable in itself as a therapeutic strategy, the status of apigenin as an inhibitor of CYP1A2, CYP2C9 and CYP3A4 means that it may enhance rather than inhibit the action of certain cancer medications by altering their pharmacokinetics in a beneficial way. This evidence concerns the gene CYP2C9 and cancer.